
or $\mathbf{R_{10}}$ and $\mathbf{R_{11}}$ are joined to form a substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., morpholine, piperazine, piperidine, pyrrolidine, 1-methylpyrrolidin-2-one, oxetane, azetidine, 1-methylazetidine);

$\mathbf{R_{20}}$ is represented by the following structure:




wherein substitutions include: F, Cl, Br, I, OH, SH, CF_3, CN, NO_2, substituted or unsubstituted C_1-C_5 linear or branched alkyl (e.g., methyl, methoxyethyl), substituted or unsubstituted C_1-C_5 linear or branched C(O)-alkyl (e.g., C(O)-CH_3, C(O)-CH_2-O-CH_3), SO_2-alkyl (e.g., SO_2-CH_3), C(O)-NH-alkyl, C_1-C_5 linear or branched alkyl-OH (e.g., $C(CH_3)_2CH_2$-OH, CH_2CH_2-OH), C_3-C_8 heterocyclic ring (e.g., piperidine), substituted or unsubstituted C_1-C_5 linear or branched alkoxy, $N(R)_2$, $N(R_{10})(R_{11})$, aryl, phenyl, heteroaryl, C_3-C_8 cycloalkyl, halophenyl, (benzyloxy)phenyl or any combination thereof;

n and **l** are each independently an integer between 1 and 3 (e.g., 1 or 2);

m and **k** are each independently an integer between 0 and 3 (e.g., 0);

or its pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, *N*-oxide, isotopic variant (e.g., deuterated analog), pharmaceutical product or any combination thereof.

[0012b] In another aspect of the present disclosure, there is provided a compound represented by the structure of formula **V:**



V

wherein

$\mathbf{R_1}$ is F, Cl, Br, I, OH, SH, R_8-OH, R_8-SH, -R_8-O-R_{10}, -O-R_8-O-R_{10}, CF_3, CD_3, OCD_3, CN, NO_2, NH_2, NHR, $N(R)_2$, R_8-$N(R_{10})(R_{11})$, NHC(O)-R , NHC(O)-R_{10}, COOH, C(O)O-R_{10}, C(O)-R_{10}, -$C(O)NH_2$, C(O)NHR, $C(O)N(R_{10})(R_{11})$, SO_2R, $SO_2N(R_{10})(R_{11})$, $NHSO_2(R_{10})$, C_1-C_5 linear or branched, substituted or unsubstituted alkyl, C_1-C_5 linear, branched or cyclic haloalkyl, C_1-C_5 linear, branched or cyclic alkoxy, C_1-C_5 linear or branched thioalkoxy, C_1-C_5 linear or branched haloalkoxy, C_1-C_5 linear or branched alkoxyalkyl, substituted or unsubstituted C_3-C_8 cycloalkyl, substituted or unsubstituted C_3-C_8 heterocyclic ring, substituted or unsubstituted aryl;

$\mathbf{R_3}$ is F, Cl, Br, I, OH, SH, CF_3, CD_3, OCD_3, CN, NO_2, NH_2, $N(R_{10})(R_{11})$, C(O)-R_{10}, -$C(O)NH_2$, $C(O)N(R_{10})(R_{11})$, - SO_2R, $SO_2N(R_{10})(R_{11})$, C_1-C_5 linear or branched, substituted or unsubstituted alkyl, C_1-C_5 linear, branched or cyclic haloalkyl, C_1-C_5 linear, branched or cyclic alkoxy, optionally wherein at least one methylene group in the alkoxy is replaced with an oxygen atom,

substituted or unsubstituted C_3-C_8 cycloalkyl, substituted or unsubstituted, single, spirocyclic, fused, or bridged C_3-C_{10} heterocyclic ring, substituted or unsubstituted aryl;

$\mathbf{X_1}$ and $\mathbf{X_2}$ are each independently C or N;

$\mathbf{X_3}$ is N**;**

$\mathbf{X_4}$ is C or N;

$\mathbf{X_5}$ in C or N;

R is H, OH, C_1-C_5 substituted or unsubstituted alkyl;

$\mathbf{R_8}$ is $[\mathbf{CH_2}]_p$

wherein **p** is between 1 and 10;


$\mathbf{R_{10}}$ and $\mathbf{R_{11}}$ are each independently H, substituted or unsubstituted C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched alkoxy, substituted or unsubstituted C_3-C_8 heterocyclic ring;

or $\mathbf{R_{10}}$ and $\mathbf{R_{11}}$ are joined to form a substituted or unsubstituted C_3-C_8 heterocyclic ring,

wherein substitutions are selected from: F, Cl, Br, I, OH, SH, CF_3, CN, NO_2, C_1-C_5 linear or branched alkyl, methoxyethyl, C_1-C_5 linear or branched C(O)-alkyl, C(O)-CH_2-O-CH_3, SO_2-alkyl, C(O)-NH-alkyl, C_1-C_5 linear or branched alkyl-OH, $C(CH_3)_2CH_2$-OH, CH_2CH_2-OH, C_3-C_8 heterocyclic ring, substituted or unsubstituted C_1-C_5 linear or branched alkoxy, $N(R_{10})(R_{11})$, aryl, phenyl, heteroaryl, C_3-C_8 cycloalkyl or any combination thereof;

or its pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, *N*-oxide, isotopic variant, or any combination thereof.

[0012c] In another aspect of the present disclosure, there is provided a compound, represented by the structure of formula **VIII**:



VIII;




wherein

$\mathbf{R_1}$ is F, Cl, Br, I, OH, SH, R_8-OH (e.g. CH_2OH), R_8-SH, -R_8-O-R_{10} (e.g., CH_2-CH_2-O-CH_3, CH_2-O-CH_2-CH_2-O-CH_3, CH_2-O-CH_3), -O-R_8-O-R_{10} (e.g., O-CH_2-CH_2-O-CH_3), R_8-(C_3-C_8 cycloalkyl), R_8-(C_3-C_8 heterocyclic ring), CF_3, CD_3, OCD_3, CN, NO_2, -CH_2CN, -

wherein substitutions include: F, Cl, Br, I, OH, SH, CF_3, CN, NO_2, substituted or unsubstituted C_1-C_5 linear or branched alkyl (e.g., methyl, methoxyethyl), substituted or unsubstituted C_1-C_5 linear or branched C(O)-alkyl (e.g., C(O)-CH_3, C(O)-CH_2-O-CH_3), SO_2-alkyl (e.g., SO_2-CH_3), C(O)-NH-alkyl, C_1-C_5 linear or branched alkyl-OH (e.g., $C(CH_3)_2CH_2$-OH, CH_2CH_2-OH), C_3-C_8 heterocyclic ring (e.g., piperidine), substituted or unsubstituted C_1-C_5 linear or branched alkoxy, $N(R)_2$, $N(R_{10})(R_{11})$, aryl, phenyl, heteroaryl, C_3-C_8 cycloalkyl, halophenyl, (benzyloxy)phenyl or any combination thereof;


or its pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, *N*-oxide, isotopic variant (e.g., deuterated analog), pharmaceutical product or any combination thereof**.**

[0012d] In a further aspect of the present disclosure, there is provided a compound, selected from the following:

Compound Number	**Compound Structure**
305	
306	
312	

WHAT IS CLAIMED:

1. A compound represented by the structure of formula **I**:



I

wherein

A ring is a single or fused aromatic or heteroaromatic ring system (e.g., phenyl, thiophene, imidazole, pyrazole, pyrimidine, 2-, 3- or 4-pyridine, benzimidazole, indole, benzothiazole, benzooxazole, imidazopyridin, pyrazolopyridine, pyrrolopyridine, pyridazine, or pyrazine), or a single or fused C_3-C_{10} cycloalkyl (e.g. pyrrolidin-2-one) or a single or fused C_3-C_{10} heterocyclic ring (e.g., morpholine, piperidine, piperazine, tetrahydro-2H-pyran, azetidine, pyrrolidin-2-one);

B ring is a single or fused heteroaromatic ring system selected from the group consisting of: pyrimidine, pyridazine, thiophene, thiazole, pyrrole, imidazole, or indazole; or a single or fused C_3-C_{10} cycloalkyl (e.g. bicyclo[1.1.1]pentyl, cyclobutyl, cyclohexyl, cyclopentyl) or a single or fused C_3-C_{10} heterocyclic ring (e.g., morpholine, piperidine, piperazine, tetrahydro-2H-pyran, azetidine, pyrrolidin-2-one);

R_1 is F, Cl, Br, I, SH, R_8-OH (e.g. CH_2OH), R_8-SH, -R_8-O-R_{10} (e.g., CH_2-CH_2-O-CH_3, CH_2-O-CH_2-CH_2-O-CH_3, CH_2-O-CH_3), -O-R_8-O-R_{10} (e.g., O-CH_2-CH_2-O-CH_3), R_8-(C_3-C_8 cycloalkyl), R_8-(C_3-C_8 heterocyclic ring), CF_3, CD_3, OCD_3, CN, NO_2, -CH_2CN, -R_8CN, NH_2, NHR, $N(R)_2$, R_8-$N(R_{10})(R_{11})$ (e.g., CH_2-NH-CH_3, CH_2-NH-C(O)CH_3, CH_2-$N(CH_3)_2$), R_9-R_8-$N(R_{10})(R_{11})$, $B(OH)_2$, -OC(O)CF_3, -OCH_2Ph, NHC(O)-R (e.g., NHCO-Ph, NHCO-CH_3) , NHC(O)-R_{10} (e.g., NHCO-CH_3), NHCO-$N(R_{10})(R_{11})$, COOH, -C(O)Ph, C(O)O-R_{10}, R_8-C(O)-R_{10}, C(O)H, C(O)-R_{10}, C_1-C_5 linear or branched C(O)-haloalkyl, -C(O)NH_2, C(O)NHR (e.g., C(O)NH-Ph), C(O)$N(R_{10})(R_{11})$, SO_2R, $SO_2N(R_{10})(R_{11})$, $NHSO_2(R_{10})$ (e.g., $NHSO_2CH_3$), $CH(CF_3)(NH\text{-}R_{10})$, C_1-C_5 linear or branched, substituted or unsubstituted alkyl (e.g., methyl, ethyl), C_1-C_5 linear or branched, substituted or unsubstituted alkenyl, C_1-C_5 linear, branched or cyclic haloalkyl (e.g., CHF_2), C_1-C_5 linear, branched or cyclic alkoxy (e.g. methoxy), optionally wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom, C_1-C_5 linear or branched thioalkoxy, C_1-C_5 linear or branched haloalkoxy, C_1-C_5 linear or branched alkoxyalkyl, substituted or unsubstituted C_3-C_8 cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., azetidine, pyridine), substituted or unsubstituted aryl (e.g., phenyl) or substituted or unsubstituted benzyl;

R_2 is H, F, Cl, Br, I, OH, SH, R_8-OH (e.g. CH_2OH), R_8-SH, -R_8-O-R_{10} (e.g., CH_2-CH_2-O-CH_3, CH_2-O-CH_2-CH_2-O-CH_3, CH_2-O-CH_3), -O-R_8-O-R_{10} (e.g., O-CH_2-CH_2-O-CH_3), R_8-(C_3-C_8

cycloalkyl), R_8-(C_3-C_8 heterocyclic ring), CF_3, CD_3, OCD_3, CN, NO_2, -CH_2CN, -R_8CN, NH_2, NHR, $N(R)_2$, R_8-$N(R_{10})(R_{11})$ (e.g., CH_2-NH-CH_3, CH_2-NH-C(O)CH_3, CH_2-$N(CH_3)_2$), R_9-R_8-$N(R_{10})(R_{11})$, $B(OH)_2$, -OC(O)CF_3, -OCH_2Ph, NHC(O)-R (e.g., NHCO-Ph, NHCO-CH_3) , NHC(O)-R_{10} (e.g., NHCO-CH_3), NHCO-$N(R_{10})(R_{11})$, COOH, -C(O)Ph, C(O)O-R_{10}, R_8-C(O)-R_{10}, C(O)H, C(O)-R_{10}, C_1-C_5 linear or branched C(O)-haloalkyl, -$C(O)NH_2$, C(O)NHR (e.g., C(O)NH-Ph), $C(O)N(R_{10})(R_{11})$, SO_2R, $SO_2N(R_{10})(R_{11})$, $NHSO_2(R_{10})$ (e.g., $NHSO_2CH_3$), $CH(CF_3)(NH\text{-}R_{10})$, C_1-C_5 linear or branched, substituted or unsubstituted alkyl (e.g., methyl, ethyl), C_1-C_5 linear or branched, substituted or unsubstituted alkenyl, C_1-C_5 linear, branched or cyclic haloalkyl (e.g., CHF_2), C_1-C_5 linear, branched or cyclic alkoxy (e.g. methoxy), optionally wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom, C_1-C_5 linear or branched thioalkoxy, C_1-C_5 linear or branched haloalkoxy, C_1-C_5 linear or branched alkoxyalkyl, substituted or unsubstituted C_3-C_8 cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., azetidine, pyridine), substituted or unsubstituted aryl (e.g., phenyl) or substituted or unsubstituted benzyl;

or $\mathbf{R_2}$ and $\mathbf{R_1}$ are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic (e.g., benzene) or heterocyclic (e.g., 1,4-dioxane, 2,3-dihydro-1,4-dioxine, dioxol, dioxolpyridine) ring;

$\mathbf{R_3}$ is F, Cl, Br, I, OH, SH, R_8-OH, R_8-SH, -R_8-O-R_{10} (e.g., CH_2-CH_2-O-CH_3, CH_2-O-CH_2-CH_2-O-CH_3), R_8-(C_3-C_8 cycloalkyl), R_8-(C_3-C_8 heterocyclic ring), CF_3, CD_3, OCD_3, -CH_2CN, -R_8CN, NH_2, NHR, $N(R)_2$, $N(R_{10})(R_{11})$ (e.g., morpholine, piperazine), R_8-$N(R_{10})(R_{11})$, R_9-R_8-$N(R_{10})(R_{11})$, $B(OH)_2$, -OC(O)CF_3, -OCH_2Ph, NHC(O)-R_{10}, NHCO-$N(R_{10})(R_{11})$, COOH, -C(O)Ph, C(O)O-R_{10}, R_8-C(O)-R_{10}, C(O)H, C(O)-R_{10}, C_1-C_5 linear or branched C(O)-haloalkyl, -$C(O)NH_2$, C(O)NHR (e.g., C(O)NH$(CH_3)_2$O-CH_3), $C(O)N(R_{10})(R_{11})$ (e.g., C(O)-piperidine, C(O)-pyrrolidine, C(O)$N(CH_3)_2$, C(O)-piperazine), SO_2R, $SO_2N(R_{10})(R_{11})$, $CH(CF_3)(NH\text{-}R_{10})$, C_1-C_5 linear or branched, substituted or unsubstituted alkyl (e.g., methyl, ethyl), C_1-C_5 linear or branched, substituted or unsubstituted alkenyl, C_1-C_5 linear, branched or cyclic haloalkyl (e.g., CHF_2), C_1-C_5 linear, branched or cyclic alkoxy (e.g. methoxy, 1-(methylsulfonyl)piperidin-4-oxy, 1-(methyl)piperidin-4-oxy, 1-(ethanone)piperidin-4-oxy), optionally wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom, C_1-C_5 linear or branched thioalkoxy, C_1-C_5 linear or branched haloalkoxy, C_1-C_5 linear or branched alkoxyalkyl, substituted or unsubstituted C_3-C_8 cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted, single, spirocyclic, fused, or bridged C_3-C_{10} heterocyclic ring (e.g., piperazine, 1-(2-methoxyethyl)piperazine, 1-, or 4-methylpiperazine, 1- or 4-(methylsulfonyl)piperazine, 1- or 4-(methylsulfonyl)piperidine, 2-methoxy-1-(piperazin-1-yl)ethenone, , 1-(piperazin-1-yl)ethanone, 2-(dimethylamino)-1-(piperazin-1-yl)ethanone, 2-(dimethylamino)-1-(piperazin-1-yl)propanone, 2-hydroxy-1-(piperazin-1-yl)ethenone, *N*-methylpiperazine-1-carboxamide piperidin-4-ol, piperidin-3-ol, morpholine, 3-methylmorpholine, 3-hydroxypiperidine, tetrahydro-*2H*-pyrane, tetrahydro-2H-thiopyran 1,1-dioxide, pyrazole, thiazole, imidazole, pyrrolidine, pyrrolidinone, octahydropyrrolo[1,2-α]pyrazine, 6-methyl-2,6-diazaspiro[3.3]heptane, 2-oxa-7-azaspiro[3.5]nonane, 1-(2,6-diazaspiro[3.3]heptan-2-yl)ethenone, 2-methoxy-1-(2,6-diazaspiro[3.3]heptan-2-yl)ethenone, 2,8-

diazaspiro[4.5]decan-1-one, 2-oxa-7-azaspiro[3.5]nonane), substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted benzyl;

R_4 is H, F, Cl, Br, I, OH, SH, R_8-OH, R_8-SH, -R_8-O-R_{10} (e.g., CH_2-CH_2-O-CH_3, CH_2-O-CH_2-CH_2-O-CH_3), R_8-(C_3-C_8 cycloalkyl), R_8-(C_3-C_8 heterocyclic ring), CF_3, CD_3, OCD_3, CN, NO_2, -CH_2CN, -R_8CN, NH_2, NHR, $N(R)_2$, $N(R_{10})(R_{11})$ (e.g., morpholine, piperazine), R_8-$N(R_{10})(R_{11})$, R_9-R_8-$N(R_{10})(R_{11})$, $B(OH)_2$, -$OC(O)CF_3$, -OCH_2Ph, NHC(O)-R_{10}, NHCO-$N(R_{10})(R_{11})$, COOH, -C(O)Ph, C(O)O-R_{10}, R_8-C(O)-R_{10}, C(O)H, C(O)-R_{10}, C_1-C_5 linear or branched C(O)-haloalkyl, -$C(O)NH_2$, C(O)NHR (e.g., $C(O)NH(CH_3)_2O$-CH_3), $C(O)N(R_{10})(R_{11})$ (e.g., C(O)-piperidine, C(O)-pyrrolidine, $C(O)N(CH_3)_2$, C(O)-piperazine), SO_2R, $SO_2N(R_{10})(R_{11})$, $CH(CF_3)(NH$-$R_{10})$, C_1-C_5 linear or branched, substituted or unsubstituted alkyl (e.g., methyl, ethyl), C_1-C_5 linear or branched, substituted or unsubstituted alkenyl, C_1-C_5 linear, branched or cyclic haloalkyl (e.g., CHF_2), C_1-C_5 linear, branched or cyclic alkoxy (e.g. methoxy, 1-(methylsulfonyl)piperidin-4-oxy, 1-(methyl)piperidin-4-oxy, 1-(ethanone)piperidin-4-oxy), optionally wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom, C_1-C_5 linear or branched thioalkoxy, C_1-C_5 linear or branched haloalkoxy, C_1-C_5 linear or branched alkoxyalkyl, substituted or unsubstituted C_3-C_8 cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted, single, spirocyclic, fused, or bridged C_3-C_{10} heterocyclic ring (e.g., piperazine, 1-(2-methoxyethyl)piperazine, 1-, or 4-methylpiperazine, 1- or 4-(methylsulfonyl)piperazine, 1- or 4-(methylsulfonyl)piperidine, 2-methoxy-1-(piperazin-1-yl)ethenone, , 1-(piperazin-1-yl)ethanone, 2-(dimethylamino)-1-(piperazin-1-yl)ethanone, 2-(dimethylamino)-1-(piperazin-1-yl)propanone, 2-hydroxy-1-(piperazin-1-yl)ethenone, *N*-methylpiperazine-1-carboxamide piperidin-4-ol, piperidin-3-ol, morpholine, 3-methylmorpholine, 3-hydroxypiperidine, tetrahydro-*2H*-pyrane, tetrahydro-2H-thiopyran 1,1-dioxide, pyrazole, thiazole, imidazole, pyrrolidine, pyrrolidinone, octahydropyrrolo[1,2-α]pyrazine, 6-methyl-2,6-diazaspiro[3.3]heptane, 2-oxa-7-azaspiro[3.5]nonane, 1-(2,6-diazaspiro[3.3]heptan-2-yl)ethenone, 2-methoxy-1-(2,6-diazaspiro[3.3]heptan-2-yl)ethenone, 2,8-diazaspiro[4.5]decan-1-one, 2-oxa-7-azaspiro[3.5]nonane), substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted benzyl;

or **R_3** and **R_4** are joined together to form a 5 or 6 membered substituted or unsubstituted, aliphatic (e.g., cyclopentene) or aromatic, carbocyclic (e.g., benzene) or heterocyclic (e.g., thiophene, furane, pyrrol, pyrazole) ring;

R_5 is H, **R_{20}**, F, Cl, Br, I, CF_3, -C(O)Ph, C(O)-R_{10}, C_1-C_5 linear or branched C(O)-haloalkyl, -$C(O)NH_2$, C(O)NHR, $C(O)N(R_{10})(R_{11})$, SO_2R, $SO_2N(R_{10})(R_{11})$, C_1-C_5 linear or branched, substituted or unsubstituted alkyl (e.g., methyl, ethyl), C_1-C_5 linear, branched or cyclic haloalkyl (e.g., CHF_2), substituted or unsubstituted C_3-C_8 cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted C_3-C_8 heterocyclic ring, substituted or unsubstituted aryl, or substituted or unsubstituted benzyl;

Q_1 is NH, S, or O;

G=X is C=O, C=S, S=O or SO_2;

R is H, OH, F, Cl, Br, I, CN, CF_3, NO_2, NH_2, $NH(R_{10})$ (e.g., $NH(CH_3)$), $N(R_{10})(R_{11})$, R_{20}, C_1-C_5 linear or branched, C_1-C_5 substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH_2CH_2OH,

$CH_2CH_2OCH_3$), R_8-R_{10} (e.g., CH_2-OH, CH_2CH_2-OH), C(O)-R_{10} (e.g., C(O)-methylpyrroldine, C(O)-methylpiperidine, C(O)-CH_3), C_1-C_5 substituted or unsubstituted C(O)-alkyl (e.g., C(O)-CH_2CH_2-OCH_3, C(O)-CH_3, C(O)-CH_2-$N(CH_3)_2$, C(O)-CH_2-CH_2-$N(CH_3)_2$, C(O)-CH_2-OH), C(O)-R_8-R_{10} (e.g., C(O)-CH_2CH_2-OH), C(O)-substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., C(O)-methylpyrroldine, C(O)-methylpiperidine), C_1-C_5 substituted or unsubstituted SO_2-alkyl (e.g., SO_2-CH_3), C_1-C_5 substituted or unsubstituted C(O)-NH-alkyl (e.g., C(O)-NH-CH_3), C_1-C_5 linear or branched C(O)-O-alkyl (e.g., C(O)-O-tBu), C_1-C_5 linear or branched alkoxy, -R_8-O-R_{10} (e.g., CH_2-CH_2-O-CH_3), C_1-C_5 linear or branched haloalkyl (e.g., CF_3, CF_2CH_3, CH_2CF_3, $CF_2CH_2CH_3$, $CH_2CH_2CF_3$, $CF_2CH(CH_3)_2$,$CF(CH_3)$-$CH(CH_3)_2$), R_8-aryl (e.g., CH_2-Ph), substituted or unsubstituted aryl (e.g., phenyl), or substituted or unsubstituted heteroaryl (e.g., pyridine (2, 3, and 4-pyridine); or

two geminal **R** substitutions are joined together to form a 3 - 6 membered substituted or unsubstituted, aliphatic (e.g., cyclopropyl, cyclopentene) or aromatic, carbocyclic (e.g., benzene) or heterocyclic (e.g., thiophene, furane, pyrrol, pyrazole) ring;

R_8 is $[\mathbf{CH_2}]_p$

wherein **p** is between 1 and 10 (e.g., 2);


R_9 is $[CH]_q$, $[C]_q$

wherein **q** is between 2 and 10;

R_{10} and **R_{11}** are each independently H, OH, substituted or unsubstituted C_1-C_5 linear or branched alkyl (e.g., methyl, ethyl, CH_2-CH_2-O-CH_3), C_1-C_5 linear or branched alkoxy (e.g., O-CH_3), substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., 1-(methylsulfonyl)piperidine, 1-(methylsulfonyl)piperazine, tetrahydro-*2H*-pyrane, morpholine, thiomorpholine 1,1-dioxide, methyl-pyrrolidine, methyl-piperidine), C(O)-alkyl, or $S(O)_2$-alkyl;

or **R_{10}** and **R_{11}** are joined to form a substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., morpholine, piperazine, piperidine, pyrrolidine, 1-methylpyrrolidin-2-one, oxetane, azetidine, 1-methylazetidine);

R_{20} is represented by the following structure:









wherein substitutions include: F, Cl, Br, I, OH, SH, CF_3, CN, NO_2, substituted or unsubstituted C_1-C_5 linear or branched alkyl (e.g., methyl, methoxyethyl), substituted or unsubstituted C_1-C_5 linear or branched C(O)-alkyl (e.g., C(O)-CH_3, C(O)-CH_2-O-CH_3), SO_2-alkyl (e.g., SO_2-CH_3), C(O)-NH-alkyl, C_1-C_5 linear or branched alkyl-OH (e.g., $C(CH_3)_2CH_2$-OH, CH_2CH_2-OH), C_3-C_8 heterocyclic ring (e.g., piperidine), substituted or unsubstituted C_1-C_5 linear or branched alkoxy, $N(R)_2$, $N(R_{10})(R_{11})$, aryl, phenyl, heteroaryl, C_3-C_8 cycloalkyl, halophenyl, (benzyloxy)phenyl or any combination thereof;







n and **l** are each independently an integer between 1 and 3 (e.g., 1 or 2);





m and **k** are each independently an integer between 0 and 3 (e.g., 0);





or its pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, *N*-oxide, isotopic variant (e.g., deuterated analog), pharmaceutical product or any combination thereof.





2. The compound of claim 1, represented by the following structures:




Compound Number	Compound Structure
317	
320	
324	
345	
349	
355	





356	
358	
360	
363	
366	
373	





374	
416	
417	
418	

419	
420	
421	
422	


423	
424	
425	
426	

427	
428	
429	

430	
431	
432	
433	

434	
435	
462	
463	

3. A compound represented by the structure of formula **V:**



V

wherein

R_1 is F, Cl, Br, I, OH, SH, R_8-OH, R_8-SH, -R_8-O-R_{10}, -O-R_8-O-R_{10}, CF_3, CD_3, OCD_3, CN, NO_2, NH_2, NHR, $N(R)_2$, R_8-$N(R_{10})(R_{11})$, NHC(O)-R , NHC(O)-R_{10}, COOH, C(O)O-R_{10}, C(O)-R_{10}, -$C(O)NH_2$, C(O)NHR, $C(O)N(R_{10})(R_{11})$, SO_2R, $SO_2N(R_{10})(R_{11})$, $NHSO_2(R_{10})$, C_1-C_5 linear or branched, substituted or unsubstituted alkyl, C_1-C_5 linear, branched or cyclic haloalkyl, C_1-C_5 linear, branched or cyclic alkoxy, C_1-C_5 linear or branched thioalkoxy, C_1-C_5 linear or branched haloalkoxy, C_1-C_5 linear or branched alkoxyalkyl, substituted or unsubstituted C_3-C_8 cycloalkyl, substituted or unsubstituted C_3-C_8 heterocyclic ring, substituted or unsubstituted aryl;

R_3 is F, Cl, Br, I, OH, SH, CF_3, CD_3, OCD_3, CN, NO_2, NH_2, $N(R_{10})(R_{11})$, C(O)-R_{10}, -$C(O)NH_2$, $C(O)N(R_{10})(R_{11})$, - SO_2R, $SO_2N(R_{10})(R_{11})$, C_1-C_5 linear or branched, substituted or unsubstituted alkyl, C_1-C_5 linear, branched or cyclic haloalkyl, C_1-C_5 linear, branched or cyclic alkoxy, optionally wherein at least one methylene group in the alkoxy is replaced with an oxygen atom, substituted or unsubstituted C_3-C_8 cycloalkyl, substituted or unsubstituted, single, spirocyclic, fused, or bridged C_3-C_{10} heterocyclic ring, substituted or unsubstituted aryl;

X_1 and **X_2** are each independently C or N;

X_3 is N**;**

X_4 is C or N;

X_5 in C or N;

R is H, OH, C_1-C_5 substituted or unsubstituted alkyl;

R_8 is $[\mathbf{CH_2}]_p$

wherein **p** is between 1 and 10;






R_{10} and **R_{11}** are each independently H, substituted or unsubstituted C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched alkoxy, substituted or unsubstituted C_3-C_8 heterocyclic ring;






or **R_{10}** and **R_{11}** are joined to form a substituted or unsubstituted C_3-C_8 heterocyclic ring,






wherein substitutions are selected from: F, Cl, Br, I, OH, SH, CF_3, CN, NO_2, C_1-C_5 linear or branched alkyl, methoxyethyl, C_1-C_5 linear or branched C(O)-alkyl, C(O)-CH_2-O-CH_3, SO_2-alkyl, C(O)-NH-alkyl, C_1-C_5 linear or branched alkyl-OH, $C(CH_3)_2CH_2$-OH, CH_2CH_2-OH, C_3-C_8 heterocyclic ring, substituted or unsubstituted C_1-C_5 linear or branched alkoxy, $N(R_{10})(R_{11})$, aryl, phenyl, heteroaryl, C_3-C_8 cycloalkyl or any combination thereof;





or its pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, *N*-oxide, isotopic variant, or any combination thereof.





4. The compound of claim 3, represented by any of the following structures:






Compound Number	Compound Structure
330	
366	
367	
371	
372	







373	
381	
383	
403	
437	







438	
439	
440	
442	
443	








444	
445	
446	
447	







448	
449	
450	
452	

453	
454	
455	
456	
457	


459	
460	
461	
464	
465	
466	

467	
468	
469	
470	
471	
472	

475	
476	
477	
478	
479	
480	
481	

482	
483	
485	
486	
487	
488	

5. A compound, represented by the structure of formula **VIII**:



VIII;

wherein

R_1 is F, Cl, Br, I, OH, SH, R_8-OH (e.g. CH_2OH), R_8-SH, -R_8-O-R_{10} (e.g., CH_2-CH_2-O-CH_3, CH_2-O-CH_2-CH_2-O-CH_3, CH_2-O-CH_3), -O-R_8-O-R_{10} (e.g., O-CH_2-CH_2-O-CH_3), R_8-(C_3-C_8 cycloalkyl), R_8-(C_3-C_8 heterocyclic ring), CF_3, CD_3, OCD_3, CN, NO_2, -CH_2CN, -R_8CN, NH_2, NHR, $N(R)_2$, R_8-$N(R_{10})(R_{11})$ (e.g., CH_2-NH-CH_3, CH_2-NH-C(O)CH_3, CH_2-$N(CH_3)_2$), NHC(O)-R (e.g., NHCO-Ph, NHCO-CH_3) , NHC(O)-R_{10} (e.g., NHCO-CH_3), NHCO-$N(R_{10})(R_{11})$, COOH, -C(O)Ph, C(O)O-R_{10}, R_8-C(O)-R_{10}, C(O)-R_{10}, -$C(O)NH_2$, C(O)NHR (e.g., C(O)NH-Ph), $C(O)N(R_{10})(R_{11})$, SO_2R, $SO_2N(R_{10})(R_{11})$, $NHSO_2(R_{10})$ (e.g., $NHSO_2CH_3$), C_1-C_5 linear or branched, substituted or unsubstituted alkyl (e.g., methyl, ethyl), C_1-C_5 linear, branched or cyclic haloalkyl (e.g., CHF_2), C_1-C_5 linear, branched or cyclic alkoxy (e.g. methoxy), optionally wherein at least one methylene group (CH_2) in the alkoxy is replaced with an oxygen atom, C_1-C_5 linear or branched thioalkoxy, C_1-C_5 linear or branched haloalkoxy, C_1-C_5 linear or branched alkoxyalkyl, substituted or unsubstituted C_3-C_8 cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., azetidine, pyridine), or substituted or unsubstituted aryl (e.g., phenyl);

X_3 is N;

X_1, **X_2** **X_4** and **X_5** are each independently C or N;

X_6 is O, CH_2, CHR (e.g., CH(OH), $CH(NH_2)$, $CH(NH(CH_3))$), $C(R_{10})(R_{11})$ (e.g., $C(H)CH_2CH_2$-OH, $C(H)CH_2$-OH, 1-methylazetidine), NH, N-R (e.g., N-CH_3, N-SO_2-CH_3, N-R_{20}, N-CH_2CH_2-OCH_3,) or N-C(O)-R_{10} (e.g., N-C(O)O-tBu, N-C(O)-CH_2CH_2-OCH_3, N-C(O)-CH_3, N-C(O)-CH_2-$N(CH_3)_2$, N-C(O)-CH_2-CH_2-$N(CH_3)_2$, N-C(O)-CH_2-OH, N-C(O)-CH_2CH_2-OH, N-C(O)-NH-CH_3, N-C(O)-1-methyl-2-pyrrolidine, N-C(O)-1-methyl-3-pyrrolidine, N-C(O)-1-methyl-3-piperidine, N-C(O)-1-methyl-4-piperidine);

R is H, OH, NH_2, $NH(R_{10})$ (e.g., $NH(CH_3)$), $N(R_{10})(R_{11})$, C_1-C_5 linear or branched, C_1-C_5 substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH_2CH_2OH, $CH_2CH_2OCH_3$), or C_1-C_5 substituted or unsubstituted SO_2-alkyl (e.g., SO_2-CH_3)

R_8 is $[\mathbf{CH_2}]_p$

wherein **p** is between 1 and 10 (e.g., 2);

R_{10} and **R_{11}** are each independently H, OH, substituted or unsubstituted C_1-C_5 linear or branched alkyl (e.g., methyl, ethyl, CH_2-CH_2-O-CH_3), C_1-C_5 linear or branched alkoxy (e.g., O-CH_3), substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., 1-(methylsulfonyl)piperidine, 1-




(methylsulfonyl)piperazine, tetrahydro-*2H*-pyrane, morpholine, thiomorpholine 1,1-dioxide, methyl-pyrrolidine, methyl-piperidine), C(O)-alkyl, or $S(O)_2$-alkyl;





or $\mathbf{R_{10}}$ and $\mathbf{R_{11}}$ are joined to form a substituted or unsubstituted C_3-C_8 heterocyclic ring (e.g., morpholine, piperazine, piperidine, pyrrolidine, 1-methylpyrrolidin-2-one , oxetane, azetidine, 1-methylazetidine),





wherein substitutions include: F, Cl, Br, I, OH, SH, CF_3, CN, NO_2, substituted or unsubstituted C_1-C_5 linear or branched alkyl (e.g., methyl, methoxyethyl), substituted or unsubstituted C_1-C_5 linear or branched C(O)-alkyl (e.g., C(O)-CH_3, C(O)-CH_2-O-CH_3), SO_2-alkyl (e.g., SO_2-CH_3), C(O)-NH-alkyl, C_1-C_5 linear or branched alkyl-OH (e.g., $C(CH_3)_2CH_2$-OH, CH_2CH_2-OH), C_3-C_8 heterocyclic ring (e.g., piperidine), substituted or unsubstituted C_1-C_5 linear or branched alkoxy, $N(R)_2$, $N(R_{10})(R_{11})$, aryl, phenyl, heteroaryl, C_3-C_8 cycloalkyl, halophenyl, (benzyloxy)phenyl or any combination thereof;





or its pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, *N*-oxide, isotopic variant (e.g., deuterated analog), pharmaceutical product or any combination thereof**.**







6. The compound of claim 5, represented by any one of the following structures:







Compound Number	**Compound Structure**
366	
371	
372	








373	
403	
442	
443	



444	
445	
446	
447	

448	
452	
453	
454	

455	
456	
457	
458	
460	
466	

467	
468	
469	
470	
471	
472	

475	
476	
478	
479	
480	
482	
483	

485	
486	

7. The compound of claim 1, 3 or 5,

wherein $\mathbf{R_1}$ is Cl, -R_8-O-R_{10}, or CH_2-O-CH_3;

wherein $\mathbf{R_3}$, as defined in claims 1 and 3, is N(R_{10})(R_{11}) (e.g., morpholine, piperazine), substituted or unsubstituted, single, spirocyclic, fused, or bridged C_3-C_{10} heterocyclic ring (e.g., piperazine, 1-(2-methoxyethyl)piperazine, 1-, or 4-methylpiperazine, 1- or 4-(methylsulfonyl)piperazine, 1- or 4-(methylsulfonyl)piperidine, 2-methoxy-1-(piperazin-1-yl)ethenone, , 1-(piperazin-1-yl)ethanone, 2-(dimethylamino)-1-(piperazin-1-yl)ethanone, 2-(dimethylamino)-1-(piperazin-1-yl)propanone, 2-hydroxy-1-(piperazin-1-yl)ethenone, *N*-methylpiperazine-1-carboxamide piperidin-4-ol, piperidin-3-ol, morpholine, 3-methylmorpholine, 3-hydroxypiperidine, tetrahydro-*2H*-pyrane, tetrahydro-2H-thiopyran 1,1-dioxide, pyrazole, thiazole, imidazole, pyrrolidine, pyrrolidinone, octahydropyrrolo[1,2-α]pyrazine, 6-methyl-2,6-diazaspiro[3.3]heptane, 2-oxa-7-azaspiro[3.5]nonane, 1-(2,6-diazaspiro[3.3]heptan-2-yl)ethenone, 2-methoxy-1-(2,6-diazaspiro[3.3]heptan-2-yl)ethenone, 2,8-diazaspiro[4.5]decan-1-one, 2-oxa-7-azaspiro[3.5]nonane), or any combination thereof;

wherein $\mathbf{X_6}$ as defined in claim 5, is CHR, CH(OH), C(R_{10})(R_{11}), 1-methylazetidine, N-R, N-SO_2-CH_3, N-C(O)-R_{10}, N-C(O)-CH_3, N-C(O)-NH-CH_3, or N-C(O)-1-methyl-3-piperidine;

wherein **R** is H or OH;







wherein $\mathbf{R_{10}}$ is substituted or unsubstituted C_3-C_8 heterocyclic ring, methyl-piperidine, or wherein $\mathbf{R_{10}}$ and $\mathbf{R_{11}}$ are joined to form a substituted or unsubstituted C_3-C_8 heterocyclic ring or 1-methylazetidine;








or any combination thereof.







8. The compound of any one of the preceding claims, wherein at least two of $\mathbf{X_3}$, $\mathbf{X_4}$ and $\mathbf{X_5}$ are N.







9. A compound, selected from the following:







Compound Number	**Compound Structure**






305	
306	
312	
315	
319	
321	







322	
326	
327	
328	
329	
331	
332	






333	
334	
335	
336	
337	
338	






340	
341	
342	
343	
344	
346	






347	
348	
350	
351	
353	
354	






357	
361	
365	
368	
369	






375	
376	
377	
378	
379	
380	





382	
384	
385	
386	
387	



388	
389	
390	
391	
392	

393	
394	
395	
399	
400	

404	
405	
408	
409	
410	

411	
412	
413	
414	
415	

436	
441	
451	
473	

474	
484	

10. The compound according to any one of claims 1-9, wherein the compound is a collagen translation inhibitor.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier.

12. Use of a compound according to any one of claims 1 to 9, in the manufacture of a medicament for treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting fibrosis in a subject.

13. The use of claim 12,

wherein said fibrosis is a systemic fibrotic disease;

wherein said fibrosis is an organ-specific fibrotic disease;

wherein said fibrosis is primary or secondary fibrosis;

wherein said fibrosis is a result of systemic sclerosis, graft-versus host disease (GVHD), pulmonary fibrosis, autoimmune disorder, tissue injury, inflammation, oxidative stress or any combination thereof;

wherein the fibrosis is hepatic fibrosis, lung fibrosis or dermal fibrosis;

wherein said subject has a liver cirrhosis;

or any combination thereof.

14. The use of claim 13,

wherein said systemic fibrotic disease is systemic sclerosis, multifocal fibrosclerosis (IgG4-associated fibrosis), nephrogenic systemic fibrosis, sclerodermatous graft vs. host disease, or any combination thereof;

wherein said organ-specific fibrotic disease is lung fibrosis, cardiac fibrosis, kidney fibrosis, pulmonary fibrosis, liver and portal vein fibrosis, radiation-induced fibrosis, bladder fibrosis, intestinal fibrosis, peritoneal sclerosis, diffuse fasciitis, wound healing, scaring, or any combination thereof;

wherein the dermal fibrosis is scleroderma;

wherein the dermal fibrosis is a result of a localized or generalized morphea, keloids, hypertrophic scars, familial cutaneous collagenoma, connective tissue nevi of the collagen type, or any combination thereof;

wherein the hepatic fibrosis is a result of hepatic scarring or chronic liver injury;

or any combination thereof.

15. The use of claim 14,

wherein said lung fibrosis is idiopathic pulmonary fibrosis (IPF);

wherein said cardiac fibrosis is hypertension-associated cardiac fibrosis, Post-myocardial infarction, Chagas disease-induced myocardial fibrosis or any combination thereof;

wherein said kidney fibrosis is diabetic and hypertensive nephropathy, urinary tract obstruction-induced kidney fibrosis, inflammatory/autoimmune-induced kidney fibrosis, aristolochic acid nephropathy, polycystic kidney disease, or any combination thereof;

wherein said pulmonary fibrosis is idiopathic pulmonary fibrosis, silica-induced pneumoconiosis (silicosis), asbestos-induced pulmonary fibrosis (asbestosis), chemotherapeutic agent-induced pulmonary fibrosis, or any combination thereof;

wherein said liver and portal vein fibrosis is alcoholic and nonalcoholic liver fibrosis, hepatitis C-induced liver fibrosis, primary biliary cirrhosis, parasite-induced liver fibrosis (schistosomiasis), or any combination thereof;

wherein said diffuse fasciitis is localized scleroderma, keloids, dupuytren's disease, peyronie's disease, myelofibrosis, oral submucous fibrosis, or any combination thereof;

wherein the chronic liver injury results from alcoholism, malnutrition, hemochromatosis, exposure to poisons, toxins or drugs;

or any combination thereof.

16. Use of a compound according to any one of claims 1 to 9, in the manufacture of a medicament for treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting lung fibrosis, idiopathic pulmonary fibrosis (IPF), hepato-fibrotic disorder, cirrhosis, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), non alcoholic fatty liver disease (NAFLD), or an autoimmune disease in a subject.

17. The use of claim 16,







wherein the lung fibrosis is idiopathic pulmonary fibrosis (IPF),








wherein the hepato-fibrotic disorder is a portal hypertension, cirrhosis, congenital hepatic fibrosis or any combination thereof;






wherein the cirrhosis is a result of hepatitis or alcoholism;

or any combination thereof.

18. Use of a compound represented by any one of the following structures:

Compound Number	Compound Structure
300	
301	
302	
303	
304	
306	

307	
308	
310	
311	
312	
313	
316	

318	
323	
325	
339	
352	

in the manufacture of a medicament for treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting: fibrosis, lung fibrosis, idiopathic pulmonary fibrosis (IPF), hepato-fibrotic disorder, cirrhosis, alcoholic steatohepatitis (ASH) , non-alcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), non alcoholic fatty liver disease (NAFLD), or an autoimmune disease, in a subject.

19. The use of claim 18,

wherein said fibrosis is a systemic fibrotic disease;

wherein said fibrosis is an organ-specific fibrotic disease;

wherein said fibrosis is primary or secondary fibrosis;

wherein said fibrosis is a result of systemic sclerosis, graft-versus host disease (GVHD), pulmonary fibrosis, autoimmune disorder, tissue injury, inflammation, oxidative stress or any combination thereof;

wherein said subject has a liver cirrhosis;

wherein the fibrosis is hepatic fibrosis, lung fibrosis or dermal fibrosis;

wherein the lung fibrosis is idiopathic pulmonary fibrosis (IPF);

wherein the hepato-fibrotic disorder is a portal hypertension, cirrhosis, congenital hepatic fibrosis or any combination thereof;

wherein the cirrhosis is a result of hepatitis or alcoholism;

or any combination thereof.

20. The use of claim 19,

wherein said systemic fibrotic disease is systemic sclerosis, multifocal fibrosclerosis (IgG4-associated fibrosis), nephrogenic systemic fibrosis, sclerodermatous graft vs. host disease, or any combination thereof;

wherein said organ-specific fibrotic disease is lung fibrosis, cardiac fibrosis, kidney fibrosis, pulmonary fibrosis, liver and portal vein fibrosis, radiation-induced fibrosis, bladder fibrosis, intestinal fibrosis, peritoneal sclerosis, diffuse fasciitis, wound healing, scaring, or any combination thereof;

wherein the dermal fibrosis is scleroderma;

wherein the dermal fibrosis is a result of a localized or generalized morphea, keloids, hypertrophic scars, familial cutaneous collagenoma, connective tissue nevi of the collagen type, or any combination thereof;

wherein the hepatic fibrosis is a result of hepatic scarring or chronic liver injury;

or any combination thereof.

21. The use of claim 20,

wherein said lung fibrosis is idiopathic pulmonary fibrosis (IPF);

wherein said cardiac fibrosis is hypertension-associated cardiac fibrosis, Post-myocardial infarction, Chagas disease-induced myocardial fibrosis or any combination thereof;

wherein said kidney fibrosis is diabetic and hypertensive nephropathy, urinary tract obstruction-induced kidney fibrosis, inflammatory/autoimmune-induced kidney fibrosis, aristolochic acid nephropathy, polycystic kidney disease, or any combination thereof;

wherein said pulmonary fibrosis is idiopathic pulmonary fibrosis, silica-induced pneumoconiosis (silicosis), asbestos-induced pulmonary fibrosis (asbestosis), chemotherapeutic agent-induced pulmonary fibrosis, or any combination thereof;

wherein said liver and portal vein fibrosis is alcoholic and nonalcoholic liver fibrosis, hepatitis C-induced liver fibrosis, primary biliary cirrhosis, parasite-induced liver fibrosis (schistosomiasis), or any combination thereof;

wherein said diffuse fasciitis is localized scleroderma, keloids, dupuytren’s disease, peyronie’s disease, myelofibrosis, oral submucous fibrosis, or any combination thereof;

wherein the chronic liver injury results from alcoholism, malnutrition, hemochromatosis, exposure to poisons, toxins or drugs;

or any combination thereof.

22. The compound according to any one of claims 1 to 9 for use in therapy.